Relay Therapeutics Downgraded Amid Shifting Focus and Mixed Data
Relay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)
Image: Seeking Alpha
Relay Therapeutics has shifted its focus from lirafugratinib to zovegalisib, targeting vascular anomalies and breast cancer. While Phase 2 data for zovegalisib shows promise, comparisons with competitors require careful analysis. The company's valuation leads to a downgrade to 'Hold' as evidence of zovegalisib's differentiation is awaited.
- 01Relay Therapeutics is now focusing on zovegalisib after out-licensing lirafugratinib, which was initially aimed at FGFR2-altered cancers.
- 02The Phase 2 data for zovegalisib in treating vascular anomalies is supportive but needs careful interpretation against Novartis’ Vijoice.
- 03Discounted Cash Flow (DCF) models estimate zovegalisib’s risk-adjusted net present value (rNPV) at $406.5 million for vascular anomalies and $895.1 million for second-line breast cancer.
- 04Peak sales potential for zovegalisib is projected to be between $1 billion and $1.5 billion for each indication.
- 05The downgrade to 'Hold' reflects a valuation close to intrinsic equity value, pending clearer evidence of zovegalisib's competitive edge.
Advertisement
In-Article Ad
Relay Therapeutics (RLAY) has recently shifted its focus from its main drug, lirafugratinib, to zovegalisib, targeting vascular anomalies and breast cancer. Initial Phase 1/2 data for lirafugratinib in cholangiocarcinoma was previously viewed as promising. However, the company has out-licensed lirafugratinib, now concentrating on zovegalisib, which has shown supportive Phase 2 data in vascular anomalies. Analysts note that comparisons with Novartis’ Vijoice necessitate nuanced interpretation. Current financial models indicate a risk-adjusted net present value (rNPV) of $406.5 million for zovegalisib in vascular anomalies and $895.1 million for its application in second-line breast cancer, with peak sales potential estimated at $1 billion to $1.5 billion for each indication. Given these factors, the analyst has downgraded RLAY to 'Hold', suggesting that the stock is valued near its intrinsic equity value while awaiting clearer evidence of zovegalisib’s differentiation in the market.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think Relay Therapeutics will successfully differentiate zovegalisib in the market?
Connecting to poll...
More about Relay Therapeutics
Relay Therapeutics : Augmentation des prévisions de cours après des résultats d'essai positifs
Investing French • May 20, 2026
Chute des actions de Relay Therapeutics suite à une offre d'actions de 175 millions de dollars
Investing French • May 20, 2026
Las acciones de Relay Therapeutics caen tras anuncio de oferta de 175 millones de dólares
Investing • May 20, 2026
Read the original article
Visit the source for the complete story.